Veerendra Munugalavadla

Statistics

Publications

Citations

2.4K

H-Index

Active since

2003

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Indiana University School of Medicine

The Ohio State University

AstraZeneca (United States)

Vita-Salute San Raffaele University

Veerendra Munugalavadla is an author at Indiana University – Purdue University Indianapolis specializing in medicine, pharmacology, and life sciences.

ORCID

Publications per year

2003–2025

Publications

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 612 citations · Full text

Medicine, Hematology, Pharmacology +10

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor

Rebecca J. Chan, Melissa B. Leedy, Veerendra Munugalavadla et al. · Blood · 2005 · 154 citations · Full text

Life Sciences, Genetics, Molecular Genetics +7

Repression of c-Kit and Its Downstream Substrates by GATA-1 Inhibits Cell Proliferation during Erythroid Maturation

Veerendra Munugalavadla, Louis C. Doré, Bai Lin Tan et al. · Molecular and Cellular Biology · 2005 · 106 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak et al. · New England Journal of Medicine · 2025 · 103 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL

Raghuveer Singh Mali, Baskar Ramdas, Peilin Ma et al. · Cancer Cell · 2011 · 98 citations · Full text

Medicine, Molecular Biology, Oncology +14

1–5 of 49